Targets › CD27
7 programs from 6 companies in 8 trials: 4 Phase 2, 3 Phase 1, 1 Phase 3; Oncology, Immunology, Genitourinary; next expected readout Mar 2027.
Costimulatory immune-checkpoint receptor expressed at the surface of T-cells, NK-cells and B-cells which binds to and is activated by its ligand CD70/CD27L expressed by B-cells. The CD70-CD27 signaling pathway mediates antigen-specific T-cell activation and expansion which in turn provides immune surveillance of B-cells. (UniProt, P26842)
Open in Phaseline: the race on CD27, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Alpine Immune Sciences | Povetacicept (ALPN-303) Dual CD27/CD70 co-stimulation inhibitor | CD27, CD70 | Phase 3 | Immunoglobulin A Nephropathy | Jan 2028 |
| Annick Desjardins, MD | Varlilumab CD27 antigen agonist | CD27 | Phase 2 | Glioblastoma | Mar 2027 |
| Robert Samstein | Nadunolimab agonist of CD27, a TNF superfamily co-stimulatory receptor | CD27 | Phase 2 | High-risk Lung Nodules | Dec 2027 |
| National Cancer Institute (NCI) | Varlilumab CD27 antigen agonist | CD27 | Phase 2 | ALK-Positive Large B-Cell Lymphoma; Metastatic Distal Bile Duct Adenocarcinoma | – |
| Beijing Tongren Hospital | Stapokibart CD27 agonist antibody | CD27 | Phase 1 | HNSCC | Jun 2027 |
| Alpine Immune Sciences | Povetacicept (ALPN-303) CD27 costimulatory molecule inhibitor | CD27 | Phase 1 | Lupus Nephritis | Mar 2028 |
| Xilio Development | XTX501 CD27 agonist | CD27 | Phase 1 | Metastatic NSCLC - Non-Small Cell Lung Cancer | Nov 2029 |
Lupus Nephritis (1) ALK-Positive Large B-Cell Lymphoma (1) Metastatic Distal Bile Duct Adenocarcinoma (1) HNSCC (1) Metastatic NSCLC - Non-Small Cell Lung Cancer (1) Immunoglobulin A Nephropathy (1) High-risk Lung Nodules (1) Glioblastoma (1)
antibody (4), mixed (2), small molecule (1)
Alpine Immune Sciences (2) National Cancer Institute (NCI) (1) Beijing Tongren Hospital (1) Xilio Development (1) Robert Samstein (1) Annick Desjardins, MD (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.